Search

Search Constraints

You searched for: Author/Creator Campbell, P.

Search Results

5. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019)